The French firm NicOx SA stands to break the bank, to the tune of up to nearly $400 million, per terms of a technology deal with Pfizer Inc. (BioWorld International)

Basilea Shares Hit Peak On Positive Ceftobiprole Data

By Cormac Sheridan

Wednesday, March 8, 2006

Buy Reprint

No Abstract

Antisense RNA Therapy Shows Promise In Muscular Dystrophy

By Sharon Kingman

Wednesday, March 8, 2006

Buy Reprint

No Abstract

GTC Biotherapeutics’ ATryn Gets Negative Vote In Europe

By Peter O’Donnell

Wednesday, March 8, 2006

Buy Reprint

No Abstract

BioWorld

Store

Others

BioWorld-International-2006-03-08

Positive Results For ATL-104 Have Alizyme Thinking Ahead

Diabetica To Receive Up To $41M Through Amylin Deal

Other News To Note

NicOx Shares Soar On Pfizer Deal For Ophthalmic Drugs

Basilea Shares Hit Peak On Positive Ceftobiprole Data

Antisense RNA Therapy Shows Promise In Muscular Dystrophy

GTC Biotherapeutics’ ATryn Gets Negative Vote In Europe

Explore BioWorld.com

BioWorld

Store

Others

Login to Your Account

BioWorld

Store

Others

BioWorld-International-2006-03-08

Positive Results For ATL-104 Have Alizyme Thinking Ahead

Diabetica To Receive Up To $41M Through Amylin Deal

Other News To Note

NicOx Shares Soar On Pfizer Deal For Ophthalmic Drugs

Basilea Shares Hit Peak On Positive Ceftobiprole Data

Antisense RNA Therapy Shows Promise In Muscular Dystrophy

GTC Biotherapeutics’ ATryn Gets Negative Vote In Europe

Explore BioWorld.com

BioWorld

Store

Others